Opioids for low back pain

Abstract

Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries. The analgesic efficacy of opioids for acute back pain is inferred from evidence in other acute pain conditions. Opioids do not seem to expedite return to work in injured workers or improve functional outcomes of acute back pain in primary care. For chronic back pain, systematic reviews find scant evidence of efficacy. Randomized controlled trials have high dropout rates, brief duration (four months or less), and highly selected patients. Opioids seem to have short term analgesic efficacy for chronic back pain, but benefits for function are less clear. The magnitude of pain relief across chronic non-cancer pain conditions is about 30%. Given the brevity of randomized controlled trials, the long term effectiveness and safety of opioids are unknown. Loss of long term efficacy could result from drug tolerance and emergence of hyperalgesia. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates. Common short term side effects are constipation, nausea, sedation, and increased risk of falls and fractures. Longer term side effects may include depression and sexual dysfunction. Screening for high risk patients, treatment agreements, and urine testing have not reduced overall rates of opioid prescribing, misuse, or overdose. Newer strategies for reducing risks include more selective prescription of opioids and lower doses; use of prescription monitoring programs; avoidance of co-prescription with sedative hypnotics; and reformulations that make drugs more difficult to snort, smoke, or inject.

Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain

“…The high incidence of adverse effects experienced by participants in the buprenorphine group is similar to that reported in other trials of opioid analgesics, wherein 80% experienced any adverse event, with constipation (41%) and nausea (32%) being the most common (23). Despite the protocol allowing for the use of antiemetics and laxatives to manage opioid-related nausea and constipation, the use of antiemetics was limited.…”

New Therapy for Refractory Chronic Mechanical Low Back Pain—Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial

“…However, the quality of evidence for the effectiveness of these pain management techniques in this patient population is poor 8, 9, 10, 11.…”

Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test

“…2 Many individuals living with chronic pain are treated with opioid therapy. 3 To reduce opioid-related misuse and adverse events such as overdose and death, clinical guidelines recommend close monitoring of patients for aberrant behaviors using tools such as urine drug tests (UDTs) or querying state prescription drug-monitoring databases. 4,5 Evidence of high-risk behaviors, such as UDTs that are positive for illicit or non-prescribed controlled substances, may lead to discontinuation of long-term opioid therapy (LTOT).…”